^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

SORT1 positive

i
Other names: SORT1, Sortilin 1, Neurotensin Receptor 3, 100 KDa NT Receptor, Glycoprotein 95, Sortilin, Gp95, NTR3, NT3, LDLCQ6
Entrez ID:
Related biomarkers:
3years
TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. (PubMed, Cancer Sci)
Altogether, the data demonstrates the high in vivo efficacy and safety of TH1902 against TNBC through a SORT1 receptor-mediated mechanism. This property allows for selective treatment of SORT1-positive TNBC and makes TH1902 a promising avenue for personalized therapy with the potential of improving the therapeutic window of cytotoxic anticancer drugs such as docetaxel.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BCL2L1 (BCL2-like 1) • SORT1 (Sortilin 1)
|
SORT1 positive
|
docetaxel • sudocetaxel zendusortide (TH 1902)
over3years
[VIRTUAL] TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers (AACR 2021)
In all cases, TH1902 showed more potent inhibition than Docetaxel. These results strongly support future clinical development of TH1902 as novel therapeutics in SORT1+ cancers.
Preclinical
|
SORT1 (Sortilin 1)
|
SORT1 expression • SORT1 positive
|
docetaxel • sudocetaxel zendusortide (TH 1902)